199 related articles for article (PubMed ID: 35651609)
1. Hyper-IgE and Carcinoma in CADINS Disease.
Pietzsch L; Körholz J; Boschann F; Sergon M; Dorjbal B; Yee D; Gilly V; Kämmerer E; Paul D; Kastl C; Laass MW; Berner R; Jacobsen EM; Roesler J; Aust D; Lee-Kirsch MA; Snow AL; Schuetz C
Front Immunol; 2022; 13():878989. PubMed ID: 35651609
[TBL] [Abstract][Full Text] [Related]
2. Management of Atopy with Dupilumab and Omalizumab in CADINS Disease.
Diaz-Cabrera NM; Bauman BM; Iro MA; Dabbah-Krancher G; Molho-Pessach V; Zlotogorski A; Shamriz O; Dinur-Schejter Y; Sharon TD; Stepensky P; Tal Y; Eisenstein EM; Pietzsch L; Schuetz C; Abreu D; Coughlin CC; Cooper MA; Milner JD; Williams A; Armoni-Weiss G; Snow AL; Leiding JW
J Clin Immunol; 2024 Jan; 44(2):48. PubMed ID: 38231347
[TBL] [Abstract][Full Text] [Related]
3.
Hutcherson SM; Bedsaul JR; Pomerantz JL
J Immunol; 2021 Aug; 207(4):1150-1164. PubMed ID: 34341167
[TBL] [Abstract][Full Text] [Related]
4. Dominant-negative signal transducer and activator of transcription (STAT)3 variants in adult patients: A single center experience.
Shamriz O; Rubin L; Simon AJ; Lev A; Barel O; Somech R; Korem M; Matza Porges S; Freund T; Hagin D; Garty BZ; Nahum A; Molho Pessach V; Tal Y
Front Immunol; 2022; 13():1044933. PubMed ID: 36605204
[TBL] [Abstract][Full Text] [Related]
5. Expanding spectrum, intrafamilial diversity, and therapeutic challenges from 15 patients with heterozygous CARD11-associated diseases: A single center experience.
Urdinez L; Erra L; Palma AM; Mercogliano MF; Fernandez JB; Prieto E; Goris V; Bernasconi A; Sanz M; Villa M; Bouso C; Caputi L; Quesada B; Solis D; Aguirre Bruzzo A; Katsicas MM; Galluzzo L; Weyersberg C; Bocian M; Bujan MM; Oleastro M; Almejun MB; Danielian S
Front Immunol; 2022; 13():1020927. PubMed ID: 36405754
[TBL] [Abstract][Full Text] [Related]
6. Clearance of atypical cutaneous manifestations of hyper-IgE syndrome with dupilumab.
Nihal A; Comstock JR; Holland KE; Singh AM; Seroogy CM; Arkin LM
Pediatr Dermatol; 2022 Nov; 39(6):940-942. PubMed ID: 35734823
[TBL] [Abstract][Full Text] [Related]
7. Hyper IgE syndromes: clinical and molecular characteristics.
Al-Shaikhly T; Ochs HD
Immunol Cell Biol; 2019 Apr; 97(4):368-379. PubMed ID: 30264496
[TBL] [Abstract][Full Text] [Related]
8. Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation.
Siegel AM; Stone KD; Cruse G; Lawrence MG; Olivera A; Jung MY; Barber JS; Freeman AF; Holland SM; O'Brien M; Jones N; Nelson CG; Wisch LB; Kong HH; Desai A; Farber O; Gilfillan AM; Rivera J; Milner JD
J Allergy Clin Immunol; 2013 Dec; 132(6):1388-96. PubMed ID: 24184145
[TBL] [Abstract][Full Text] [Related]
9. Clinical Profile of Hyper-IgE Syndrome in India.
Saikia B; Rawat A; Minz RW; Suri D; Pandiarajan V; Jindal A; Sahu S; Karim A; Desai M; Taur PD; Pandrowala A; Gowri V; Madkaikar M; Dalvi A; Yadav RM; Lashkari HP; Raj R; Uppuluri R; Swaminathan VV; Bhattad S; Cyril G; Kumar H; Shukla A; Kalra M; Govindaraj G; Singh S
Front Immunol; 2021; 12():626593. PubMed ID: 33717144
[No Abstract] [Full Text] [Related]
10. Hyper IgE Syndromes.
Gracci S; Novelli T; D'Elios S; Bernardini R; Peroni D
Curr Pediatr Rev; 2024; 20(3):253-264. PubMed ID: 37702167
[TBL] [Abstract][Full Text] [Related]
11. Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern.
Boos AC; Hagl B; Schlesinger A; Halm BE; Ballenberger N; Pinarci M; Heinz V; Kreilinger D; Spielberger BD; Schimke-Marques LF; Sawalle-Belohradsky J; Belohradsky BH; Przybilla B; Schaub B; Wollenberg A; Renner ED
Allergy; 2014 Jul; 69(7):943-53. PubMed ID: 24898675
[TBL] [Abstract][Full Text] [Related]
12. Very Elevated IgE, Atopy, and Severe Infection: A Genomics-Based Diagnostic Approach to a Spectrum of Diseases.
Chin A; Balasubramanyam S; Davis CM
Case Reports Immunol; 2021; 2021():2767012. PubMed ID: 34603803
[TBL] [Abstract][Full Text] [Related]
13. New Dominant-Negative IL6ST Variants Expand the Immunological and Clinical Spectrum of GP130-Dependent Hyper-IgE Syndrome.
Arlabosse T; Materna M; Riccio O; Schnider C; Angelini F; Perreau M; Rochat I; Superti-Furga A; Campos-Xavier B; Héritier S; Pereira A; Deswarte C; Lévy R; Distefano M; Bustamante J; Roelens M; Borie R; Le Brun M; Crestani B; Casanova JL; Puel A; Hofer M; Fieschi C; Theodoropoulou K; Béziat V; Candotti F
J Clin Immunol; 2023 Oct; 43(7):1566-1580. PubMed ID: 37273120
[TBL] [Abstract][Full Text] [Related]
14. Key findings to expedite the diagnosis of hyper-IgE syndromes in infants and young children.
Hagl B; Heinz V; Schlesinger A; Spielberger BD; Sawalle-Belohradsky J; Senn-Rauh M; Magg T; Boos AC; Hönig M; Schwarz K; Dückers G; von Bernuth H; Pache C; Karitnig-Weiss C; Belohradsky BH; Frank J; Niehues T; Wahn V; Albert MH; Wollenberg A; Jansson AF; Renner ED
Pediatr Allergy Immunol; 2016 Mar; 27(2):177-84. PubMed ID: 26592211
[TBL] [Abstract][Full Text] [Related]
15. A Unique Heterozygous
Desjardins M; Arjunaraja S; Stinson JR; Dorjbal B; Sundaresan J; Niemela J; Raffeld M; Matthews HF; Wang A; Angelus P; Su HC; Mazer BD; Snow AL
Front Immunol; 2018; 9():2944. PubMed ID: 30619304
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab to treat severe atopic dermatitis in autosomal dominant hyper-IgE syndrome.
Sogkas G; Hirsch S; Jablonka A; Witte T; Schmidt RE; Atschekzei F
Clin Immunol; 2020 Jun; 215():108452. PubMed ID: 32360519
[No Abstract] [Full Text] [Related]
17. Inborn Error of Immunity or Atopic Dermatitis: When to be Concerned and How to Investigate.
Stadler PC; Renner ED; Milner J; Wollenberg A
J Allergy Clin Immunol Pract; 2021 Apr; 9(4):1501-1507. PubMed ID: 33548520
[TBL] [Abstract][Full Text] [Related]
18. Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease.
Dorjbal B; Stinson JR; Ma CA; Weinreich MA; Miraghazadeh B; Hartberger JM; Frey-Jakobs S; Weidinger S; Moebus L; Franke A; Schäffer AA; Bulashevska A; Fuchs S; Ehl S; Limaye S; Arkwright PD; Briggs TA; Langley C; Bethune C; Whyte AF; Alachkar H; Nejentsev S; DiMaggio T; Nelson CG; Stone KD; Nason M; Brittain EH; Oler AJ; Veltri DP; Leahy TR; Conlon N; Poli MC; Borzutzky A; Cohen JI; Davis J; Lambert MP; Romberg N; Sullivan KE; Paris K; Freeman AF; Lucas L; Chandrakasan S; Savic S; Hambleton S; Patel SY; Jordan MB; Theos A; Lebensburger J; Atkinson TP; Torgerson TR; Chinn IK; Milner JD; Grimbacher B; Cook MC; Snow AL
J Allergy Clin Immunol; 2019 Apr; 143(4):1482-1495. PubMed ID: 30170123
[TBL] [Abstract][Full Text] [Related]
19. The treatment efficacy of dupilumab in autosomal dominant hyper-immunoglobulin E syndrome with severe atopic dermatitis.
Li W; Qi Q; Wang W; Li D
Asia Pac Allergy; 2024 Mar; 14(1):39-41. PubMed ID: 38482457
[TBL] [Abstract][Full Text] [Related]
20. Combined immunodeficiency and atopy caused by a dominant negative mutation in caspase activation and recruitment domain family member 11 (CARD11).
Dadi H; Jones TA; Merico D; Sharfe N; Ovadia A; Schejter Y; Reid B; Sun M; Vong L; Atkinson A; Lavi S; Pomerantz JL; Roifman CM
J Allergy Clin Immunol; 2018 May; 141(5):1818-1830.e2. PubMed ID: 28826773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
